In a report released yesterday, Joseph Thome from TD Cowen reiterated a Buy rating on Jazz Pharmaceuticals, with a price target of $205.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Thome has given his Buy rating due to a combination of factors including Jazz Pharmaceuticals’ strong performance and future potential. The company’s Q2 revenue was in line with expectations, largely driven by the success of Xywav, which showed solid growth in patient numbers for both narcolepsy and idiopathic hypersomnia. This growth is particularly notable given the competitive market environment.
Furthermore, despite some anticipated challenges in the oncology sector, Jazz Pharmaceuticals has demonstrated confidence in the long-term growth trajectory of its marketed products. The upcoming pivotal data from the Phase III study of Ziihera in gastric esophageal adenocarcinoma is expected to be a significant catalyst, potentially offering a substantial upside to the stock. Additionally, the potential approval of dordaviprone further supports the view that Jazz Pharmaceuticals is undervalued, reinforcing the Buy recommendation.
Thome covers the Healthcare sector, focusing on stocks such as United Therapeutics, Jazz Pharmaceuticals, and Axsome Therapeutics. According to TipRanks, Thome has an average return of -3.6% and a 39.46% success rate on recommended stocks.
In another report released on July 26, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $134.00 price target.